With the steady advancement of the registration system, many enterprises are "running" into the capital market
in recent years.
According to data, in the first half of this year, there were 169 IPOs in the A-share market, with an initial financing scale of 311.
9 billion yuan, an increase of 46%
over 210.
9 billion yuan in the same period last year.
Recently, many companies have been successfully listed, including many pharmaceutical companies
.
News on December 16, Chuanning Biotechnology, a "R&D and transformation platform" in the field of synthetic biology under Kelun Pharmaceutical, opened the application, with an issue price of 5.
0 yuan per share, a single account application limit of 42,000 shares, and a market value of 420,000 yuan
for Dingge application.
According to the data, Chuanning Biotechnology belongs to the "A to A" spin-off listed company, which is the core enterprise in the field of antibiotic intermediates, and is also one of the main domestic antibiotic intermediates production bases and main supply enterprises, which is of great significance
to the stable supply of domestic antibiotic products.
In June 2021, the shareholders' meeting of Kelun Pharmaceutical agreed to spin off its subsidiary Chuanning Biotech to be listed
on the Growth Enterprise Market.
In August of the same year, Chuanning Biotech's listing application was accepted
by the Growth Enterprise Market.
On the same day, Liaoning Chunguang Pharmaceutical Equipment Co.
, Ltd.
was listed
on the Beijing Stock Exchange.
The public offering of shares does not exceed 16 million shares, the issue price is 10 yuan per share, and the funds raised are 25,000.
00 yuan, which are respectively used for the construction project of intelligent automation equipment production base and the supplementary working capital project
.
Founded in 1999, Liaoning Chunguang Pharmaceutical Equipment Co.
, Ltd.
is a modern high-tech enterprise integrating product development, production, sales and technical services, specializing in the manufacture of high-end packaging equipment for pharmaceuticals, food and daily chemicals
.
On December 14, Meihao Medical Group Co.
, Ltd.
was listed
on the Hong Kong Stock Exchange.
The global offering of 150 million shares at an issue price of HK$0.
84 per share
.
Raise up to HK$150 million, using approximately 28.
6% of the net proceeds for the potential strategic acquisition of two dental hospitals in the PRC; Approximately 27.
0% will be used to cover the capital expenditure and initial operating costs of Wenzhou Dental Development; Approximately 14.
1% will be used to cover capital expenditures and initial operating costs for the establishment of Lucheng Children's Hospital in Wenzhou; approximately 10.
0% will be used for working capital and other general corporate purposes; About 5.
4% will be used to set up a dental training centre to pool the Group's dental talents and enhance the quality of the Group's dental services.
.
.
On December 7, the exchange news, magnetic resonance imaging (MRI) upstream core component company Chenguang Medical went public
.
The stock was listed on the Beijing Stock Exchange on the same day, with an issue price of 6 yuan per share and a price-earnings ratio of 24.
29 times
.
According to the company's announcement on December 2, all the shares issued this time are new shares, the initial number of shares issued is 15 million, and the total share capital after issuance is 83.
5971 million shares, and the number of shares issued this time accounts for 17.
94% of the total share capital after the issuance (before the exercise of the over-allotment option).
It is understood that Chenguang Medical is mainly engaged in the research and development, production and sales of core hardware of superconducting MRI system and special magnets in high-tech fields, and has completed the independent research and development of four core components of high-performance high-field superconducting magnets, radio frequency systems, gradient systems and computer systems of MRI systems, has the ability to manufacture MRI machines, and has also overcome a number of special superconducting magnet manufacturing problems
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
